Abstract
The SARS-CoV-2 virus and the associatedCOVID-19disease is a pandemic that has rocked the worldin terms of public health and medical issues, business, economics and finance. Interesting and topical discussions regarding risk management of COVID-19 have been reported in leading business, economics, finance, and medical journals, as well as information and misinformation, intended or not, in the mass media. In this context, protecting the integrity of public policy pronouncements relating to the conduct andoutcomes of scientific clinical trials. In terms of protecting the scientific integrity of clinical trials of COVID-19 patients, it is intentional to determine whether imperfectly collected data on clinical trials are more useful than having no data at all.
| Original language | English |
|---|---|
| Pages (from-to) | 1-14 |
| Number of pages | 14 |
| Journal | Advances in Decision Sciences |
| Volume | 24 |
| Issue number | 1 |
| Publication status | Published - Mar 2020 |
Bibliographical note
Funding Information:* The author acknowledges the financial support of the Australian Research Council and the Ministry of Science and Technology (MOST), Taiwan.
Publisher Copyright:
© 2020 Hindawi Limited. All rights reserved.
